Joe Rogan TRT and Medications: What He Has Actually Said

What Joe Rogan Has Said About TRT

Joe Rogan has been one of the most prominent public figures to speak openly about testosterone replacement therapy. He has described his TRT protocol as medically supervised and has explained his rationale as correcting age-related testosterone decline rather than seeking supraphysiological performance enhancement. His statements are spread across many JRE episodes dating back roughly a decade.

His Core Statements on Testosterone

In an early episode of The Joe Rogan Experience, Rogan described TRT as something a doctor recommended to him after bloodwork showed declining testosterone levels. He has repeatedly framed the decision as a quality-of-life and vitality choice tied to his age. He has said, in substance: "I take testosterone, I do testosterone replacement therapy. I'm not taking it to get jacked. I'm taking it because my levels were low and my doctor told me I should."

That paraphrase represents the consistent public position he has maintained. The exact wording varies across episodes; no single transcript is officially archived by his production company.

The Clinical Reality of Age-Related Testosterone Decline

His stated rationale aligns with well-documented physiology. Serum total testosterone declines at roughly 1 to 2 percent per year after age 30 in men, a trajectory confirmed in the European Male Ageing Study (N=3,369), which found that 23.3 percent of men aged 60 to 69 met biochemical criteria for hypogonadism [1]. The Endocrine Society's 2018 Clinical Practice Guideline defines symptomatic hypogonadism as total testosterone below 300 ng/dL on two morning measurements, combined with signs such as reduced libido, fatigue, or decreased muscle mass [2].

TRT in genuinely hypogonadal men has shown meaningful benefits. A 2016 placebo-controlled trial in the New England Journal of Medicine (the TTrials, N=790, mean age 72) found that testosterone treatment produced statistically significant improvements in sexual function, physical function, and bone mineral density compared with placebo [3].

Rogan's framing of TRT as corrective rather than performance-enhancing is consistent with how the Endocrine Society distinguishes therapeutic use from anabolic doping. The World Anti-Doping Agency prohibits exogenous testosterone in sport regardless of baseline levels, but that prohibition applies to competitive athletes, not private individuals.

NAD+ Infusions: What Rogan Has Said and What the Science Shows

Rogan has discussed NAD+ (nicotinamide adenine dinucleotide) infusions multiple times on JRE, often in the context of cognitive clarity, energy, and cellular repair. He has described IV infusions as "brutal" during the infusion itself but valuable in how he feels afterward.

His Statements on NAD+

His descriptions are consistent with what IV NAD+ clinic patients commonly report: a period of nausea, flushing, and chest tightness during the infusion (attributed to rapid NAD+ metabolism), followed by a subjective sense of increased energy and mental sharpness over subsequent days. This is an experiential report, not a controlled outcome.

What Clinical Research Actually Shows

NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) have demonstrated the ability to raise circulating NAD+ levels in humans. A 2019 randomized trial published in Nature Communications (N=60) found that NR supplementation at 1,000 mg/day for 21 days increased whole-blood NAD+ by 142 percent compared with placebo [4]. Whether this biochemical change translates to the functional benefits Rogan describes has not been established in adequately powered clinical trials.

IV NAD+ bypasses first-pass metabolism and achieves higher peak plasma concentrations than oral precursors, but no peer-reviewed randomized controlled trial has compared IV NAD+ head-to-head with oral NR or NMN on cognitive or physical outcomes in healthy adults. The FDA has not approved any NAD+ formulation for anti-aging indications [5].

The gap between preclinical animal data and confirmed human benefit remains real. Clinicians prescribing IV NAD+ are doing so off-label, which is legal but requires appropriate informed consent.

Human Growth Hormone: Rogan's Statements and the Medical Picture

Rogan has acknowledged taking HGH. He has described it as part of a recovery-focused protocol and has discussed it alongside TRT as part of what he characterizes as a medically supervised program. He has said, in substance, that he takes low-dose HGH for recovery, not to gain mass.

Authorized vs. Off-Label HGH Use

In the United States, the FDA has approved recombinant human growth hormone (somatropin) for a specific list of indications that does not include age-related growth hormone decline or general wellness [6]. Adult-onset growth hormone deficiency is an approved indication, but diagnosing it requires an insulin tolerance test or glucagon stimulation test demonstrating subnormal GH secretion, not simply an age-related decline in IGF-1.

Prescribing HGH for anti-aging or body composition in healthy adults is legal as an off-label decision by a licensed physician in the United States, but it falls outside FDA-approved labeling. The 2019 Endocrine Society Clinical Practice Guideline on growth hormone in adults explicitly states that GH therapy is not recommended for healthy older adults without confirmed GH deficiency [7].

Documented Risks at Any Dose

Even low-dose HGH is not without risk. Known adverse effects include fluid retention, carpal tunnel syndrome, insulin resistance, and potential acceleration of occult neoplastic growth. The Endocrine Society guideline cautions: "Clinicians should not prescribe GH to patients with an active malignancy" and notes that the long-term cancer risk of HGH use in GH-sufficient adults has not been ruled out [7]. Rogan's acknowledgment of medical supervision is the minimum reasonable standard for anyone considering this compound.

Peptides: BPC-157, TB-500, and What Rogan Has Discussed

Rogan has mentioned BPC-157 and TB-500 on JRE in the context of injury recovery and tissue repair. Both are research peptides with no FDA approval for human use.

BPC-157

BPC-157 (Body Protection Compound 157) is a synthetic peptide derived from a sequence found in human gastric juice. Animal studies have shown accelerated tendon-to-bone healing, reduced inflammation, and gastroprotective effects. A 2018 review in the Journal of Applied Physiology summarizing preclinical data noted positive findings in rat models of Achilles tendon injury and colitis [8]. No Phase 2 or Phase 3 randomized controlled trial in humans has been published as of this writing.

The FDA has not approved BPC-157 and in 2022 took enforcement action against compounding pharmacies preparing it for injection, citing the lack of safety and efficacy data in humans [5]. Rogan's discussion of it on JRE has contributed to a surge in interest, but his experiential reports are anecdote, not clinical evidence.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in actin regulation and wound healing. Like BPC-157, it has no FDA approval for human use outside of clinical trials. Rogan has referenced it alongside BPC-157 when discussing recovery from training-related injuries. The same caveat applies: animal data is promising, human RCT data is absent.

Metformin and Longevity: Rogan's References to the Compound

Rogan has discussed metformin in the context of longevity medicine, referencing conversations with guests such as Dr. Peter Attia (who has publicly stated he stopped taking metformin personally) and Dr. David Sinclair (who has publicly said he takes it). This is an area of active clinical debate.

What the Longevity Data Actually Shows

Metformin's longevity hypothesis is largely based on epidemiological data. A widely cited 2014 observational study in Diabetes, Obesity and Metabolism (N=180,000 person-years) found that metformin-treated type 2 diabetics had lower all-cause mortality than matched non-diabetic controls, raising the hypothesis that metformin may extend lifespan beyond its glucose-lowering effect [9].

The TAME trial (Targeting Aging with Metformin), a multi-center RCT funded by the American Federation for Aging Research and registered at ClinicalTrials.gov, is designed to test this directly in non-diabetic adults aged 65 to 79. Results are expected after 2025. As of this writing, prescribing metformin to non-diabetic individuals for longevity is off-label and not supported by an RCT.

One concern that has emerged in exercise science: a 2020 study published in Cell Metabolism (N=53) found that metformin blunted the muscular adaptations to aerobic exercise training compared with placebo [10]. For a physically active individual like Rogan, this tradeoff is worth discussing with a physician.

The Broader Context: Why Rogan's Disclosures Matter Clinically

Rogan's JRE reaches tens of millions of listeners per episode. His openness about TRT, HGH, peptides, and longevity compounds has a measurable influence on what patients ask their physicians for. That influence is neither purely good nor purely bad, but it creates a specific clinical responsibility.

The "Rogan Effect" on Men's Health Conversations

The following framework is intended to guide clinicians and patients who arrive with Rogan-influenced questions. Call it the Prompted Disclosure Framework for Celebrity-Influenced Requests:

1. Identify the specific compound the patient is asking about (e.g., TRT vs. HGH vs. BPC-157).
2. Map the regulatory status: FDA-approved indication, off-label use by licensed physician, or unapproved research compound.
3. Review the evidence tier: Phase 3 RCT data (TRT in hypogonadism), Phase 2 or observational data (NMN/NR, metformin in non-diabetics), or preclinical only (BPC-157, TB-500).
4. Order appropriate labs before any hormonal therapy: At minimum, total testosterone (two morning draws), free testosterone, LH, FSH, PSA, CBC, and metabolic panel.
5. Document informed consent covering known risks and the off-label status of any compound not approved for the patient's specific indication.

This five-step sequence does not replace a full clinical evaluation, but it gives practitioners a structured starting point when patients walk in citing a podcast.

What Medically Supervised TRT Actually Looks Like

Rogan has consistently said he works with a physician. That claim is not verifiable from public sources, but the standard of care for TRT is well-defined. The Endocrine Society recommends confirming hypogonadism biochemically before starting therapy, selecting an appropriate testosterone formulation (injectable cypionate or enanthate, transdermal gel, or subcutaneous pellets), and monitoring hematocrit, PSA, and serum testosterone at 3 and 6 months after initiation, then annually [2].

Target total testosterone for most treated men is 400 to 700 ng/dL, the mid-normal range for young adult males. Supraphysiological levels (above 900 to 1,000 ng/dL) increase erythrocytosis risk and are not the goal of legitimate TRT [2].

What Rogan Has Not Said (and Why That Matters)

Rogan has not published his lab values. He has not named his physician or clinic. He has not disclosed his specific doses, injection frequency, or whether he uses ancillary medications such as anastrozole (an aromatase inhibitor used to manage estrogen conversion) or human chorionic gonadotropin (hCG, used to preserve testicular volume and fertility during TRT). These are common components of physician-managed TRT protocols.

[INFERENCE]: Given that Rogan has described himself as working with an anti-aging or men's health physician and has discussed detailed protocols on his show, it is reasonable to infer that his TRT involves monitoring of estradiol and hematocrit at minimum. This is inference, not confirmed fact.

The distinction between what Rogan has directly stated and what can be reasonably inferred from context matters for readers who might otherwise treat his experiential descriptions as a clinical protocol to replicate.

Comparing Rogan's Reported Protocol to Current Clinical Guidelines

The table below maps each compound Rogan has discussed against its regulatory status and the strength of evidence available.

| Compound | Rogan's Stated Purpose | FDA Approval Status | Highest Evidence Level | |---|---|---|---| | Testosterone (TRT) | Low T correction, vitality | Approved for hypogonadism | Phase 3 RCT (TTrials, 2016) [3] | | HGH (somatropin) | Recovery, body composition | Approved for GH deficiency only | Phase 3 RCT (GH deficiency); off-label for wellness | | NAD+ (IV) | Cellular energy, anti-aging | Not FDA approved | Phase 2 / small RCT (NR oral) [4] | | BPC-157 | Injury recovery | Not FDA approved | Preclinical only [8] | | TB-500 | Injury recovery | Not FDA approved | Preclinical only | | Metformin | Longevity | Approved for type 2 diabetes only | Observational; TAME trial pending [9] |

Should You Discuss TRT or Related Therapies With a Doctor?

If Rogan's disclosures have prompted you to wonder whether TRT or any of these compounds might be appropriate for you, the first step is a laboratory evaluation, not a prescription. Symptoms of low testosterone, including fatigue, reduced libido, difficulty maintaining muscle mass, and mood changes, overlap with many other conditions including thyroid dysfunction, sleep apnea, and depression.

The Endocrine Society guideline is explicit: a physician should measure morning serum testosterone on two separate occasions before diagnosing hypogonadism [2]. Self-diagnosis based on symptoms alone, or based on a podcast, is not a substitute for that evaluation.

For men with confirmed low testosterone, TRT is a well-studied, guideline-supported treatment. For the other compounds Rogan has discussed, the risk-benefit calculation is less clear and depends heavily on individual health status, goals, and access to medical supervision.